Literature DB >> 30470451

A 2018 overview of diuretic resistance in heart failure.

Sofia Isabel Jardim1, Luís Ramos Dos Santos2, Inês Araújo3, Filipa Marques3, Patrícia Branco4, Augusta Gaspar4, Cândida Fonseca3.   

Abstract

Heart failure is a disease with high direct and indirect costs. Current treatment includes drugs that alter disease progression and drugs that to improve symptoms. Loop diuretics are the cornerstone of congestion relief for acute management, as well as for chronic stabilization. In heart failure patients, maximal diuretic response is reduced by many individual factors. Diuretic resistance is defined as failure to achieve effective congestion relief despite appropriate or escalating diuretic doses. Its causes include impaired delivery of the diuretic to its luminal site of action, neurohormonal activation, tubular compensatory adaptation and drug interactions. Several strategies can be employed to aid decongestion of patients with impaired diuretic response. These include salt restriction, a higher effective single dose or higher dose frequency of loop diuretics, continuous infusion of diuretics and/or sequential nephron blockade through a synergistic combination of two or more diuretics from different classes. Ultrafiltration has also been found to be another effective and safe therapeutic option and should be considered in patients with refractory diuretic resistance. Overall, there is a lack of high-quality clinical data to guide the choice of treatment strategy and therapy should be tailored on a case-by-case basis.
Copyright © 2018 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Bloqueio sequencial do nefrónio; Diuretic resistance; Diuréticos de ansa; Heart failure; Insuficiência cardíaca; Loop diuretic; Resistência aos diuréticos; Sequential nephron blockade; Ultrafiltration; Ultrafiltração

Mesh:

Substances:

Year:  2018        PMID: 30470451     DOI: 10.1016/j.repc.2018.03.014

Source DB:  PubMed          Journal:  Rev Port Cardiol (Engl Ed)        ISSN: 2174-2049


  6 in total

1.  Diuretic Resistance Prediction and Risk Factor Analysis of Patients with Heart Failure During Hospitalization.

Authors:  Xiao Lu; Yi Xin; Jiang Zhu; Wei Dong; Tong-Peng Guan; Jia-Yue Li; Qin Li
Journal:  Glob Heart       Date:  2022-05-27

2.  Metolazone Add-On Therapy in Heart Failure: A Cohort Study from Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF).

Authors:  Farzad Rahimi; Mehrbod Vakhshoori; Maryam Heidarpour; Fatemeh Nouri; Kiyan Heshmat-Ghahdarijani; Mohammad Fakhrolmobasheri; Davood Shafie
Journal:  Crit Care Res Pract       Date:  2021-10-22

Review 3.  Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases.

Authors:  Yaron Ilan
Journal:  J Pers Med       Date:  2022-08-10

4.  Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF.

Authors:  Justas Simonavičius; Micha T Maeder; Casper G M J Eurlings; Arantxa Barandiarán Aizpurua; Jelena Čelutkienė; Jūratė Barysienė; Stefan Toggweiler; Beat A Kaufmann; Hans-Peter Brunner-La Rocca
Journal:  Clin Res Cardiol       Date:  2020-11-20       Impact factor: 5.460

Review 5.  Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review.

Authors:  Simge Acar; Sueda Sanli; Cinar Oztosun; Baris Afsar; Alan A Sag; Masanari Kuwabara; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2021-01-03       Impact factor: 2.370

6.  Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs.

Authors:  Ludovic Pelligand; Emilie Guillot; Anne Geneteau; Jerome Guyonnet; Reynald Magnier; Jonathan Elliott; Mathieu Peyrou; Matthieu Jacobs
Journal:  Front Vet Sci       Date:  2020-04-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.